On September 28, 2021, Pfizer Inc. announced that the first batch of participants have been dosed with the single dose quadrivalent mRNA vaccine in a Phase 1 clinical trial.

• Under the phase 1 trial, safety, tolerability, and immunogenicity of the single dose quadrivalent mRNA vaccine will be studied against influenza in healthy adults.
• mRNA influenza vaccine program of Pfizer is the first in a planned wave of programs to leverage mRNA technology for influenza.
• Pfizer has also planned to explore mRNA in other respiratory viruses and medically appropriate vaccines combinations which could provide protection against virus.
• Company has also planned to expand the development of mRNA technology in oncology and genetic diseases.